The analysis demonstrated that serum sPD-1 levels were significantly higher in patients with bone-forming tumors (osteosarcoma) compared to those with cartilage-forming tumors (chondrosarcoma, p < 0.0001). This evidence concerns the gene HOXD13 and chondrosarcoma.